COR

Cencora Inc.

COR, USA

Cencora, Inc. sources and distributes pharmaceutical products in the United States and internationally. The company's U.S. Healthcare Solutions segment distributes generic and injectable pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; distributes plasma and other blood products, vaccines, and other specialty pharmaceutical products; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and other services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; sales force services to manufacturers; and offers other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment provides international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals; and offers specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was founded in 1871 and is headquartered in Conshohocken, Pennsylvania.

https://www.cencora.com

Stock Price

$0.00

0%

decrease compared to yesterday.

Dividend

Frequency:

N/A

Rate:

N/A

Next Payout:

N/A
COR
stock
COR

Cencora: High-Growth Specialty Services Firm Disguised As A Distributor (NYSE:COR) Seeking Alpha

Read more →
COR
stock
COR

Arkadios Wealth Advisors Acquires 3,880 Shares of Cencora, Inc. $COR Defense World

Read more →

Showing 2 of 10

Analyst Ratings & Sentiment

(Last Updated 2025-09-30)

Rating:

BUY

Target Price:

$387.9333

Analyst Picks

Strong Buy

10

Buy

1

Hold

5

Sell

1

Strong Sell

0

Sentiment:

Bullish

Finn Analysis

(Last Updated 2025-09-30)

Health Score

Price to Earnings Ratio (P/E)

-

Very Low

42.38

Low 50

High 10

Price to Book Ratio (P/B)

-

Very High

43.84

Low 1

High 3

Return on Equity (ROE)

-

Very Low

-22.53 %

Low 5%

High 25%

Return on Assets (ROA)

-

Very Low

-0.44 %

Low 2%

High 10%

Free Cash Flow - Revenue % (FCF)

-

Very Low

3.44 %

Low 5%

High 15%

Debt to Equity

-

Very Low

49.63

Low 1

High 0.3

Investors

* Institutions hold a combined 77.94% of the total shares of Cencora Inc.

1.

Vanguard Group Inc

(11.5944%)

since

2025/06/30

2.

BlackRock Inc

(9.6477%)

since

2025/06/30

3.

State Street Corp

(4.3364%)

since

2025/06/30

4.

T. Rowe Price Associates, Inc.

(4.0203%)

since

2025/06/30

5.

Walgreens Boots Alliance Inc

(3.8545%)

since

2025/06/30

6.

Vanguard Total Stock Mkt Idx Inv

(2.9779%)

since

2025/07/31

7.

Geode Capital Management, LLC

(2.4694%)

since

2025/06/30

8.

Bank of America Corp

(2.4332%)

since

2025/06/30

9.

Boston Partners Global Investors, Inc

(2.2796%)

since

2025/06/30

10.

Vanguard 500 Index Investor

(2.2029%)

since

2025/07/31

11.

Vanguard Mid Cap Index Institutional

(2.1187%)

since

2025/07/31

12.

Amvescap Plc.

(2.0827%)

since

2025/06/30

13.

JPMorgan Chase & Co

(2.015%)

since

2025/06/30

14.

Wellington Management Company LLP

(1.9888%)

since

2025/06/30

15.

FMR Inc

(1.6166%)

since

2025/06/30

16.

Morgan Stanley - Brokerage Accounts

(1.5919%)

since

2025/06/30

17.

Capital Research Global Investors

(1.3644%)

since

2025/06/30

18.

NORGES BANK

(1.1959%)

since

2025/06/30

19.

Vanguard Health Care Inv

(1.1756%)

since

2025/06/30

20.

Fidelity 500 Index

(1.1278%)

since

2025/07/31

21.

Northern Trust Corp

(1.1066%)

since

2025/06/30

22.

SPDR® S&P 500® ETF

(1.0759%)

since

2025/08/31

23.

Viking Global Investors LP

(1.0737%)

since

2025/06/30

24.

iShares Core S&P 500 ETF

(1.0708%)

since

2025/08/31

25.

Bessemer Group Inc

(1.0665%)

since

2025/06/30

26.

Citadel Advisors Llc

(0.9171%)

since

2025/06/30

27.

Amundi

(0.8873%)

since

2025/06/30

28.

T. Rowe Price U.S. Value Equity Tr-D

(0.8817%)

since

2025/06/30

29.

Vanguard Value Index Inv

(0.8418%)

since

2025/07/31

30.

T. Rowe Price US Value Equity Composite

(0.7351%)

since

2025/06/30

31.

T. Rowe Price Value

(0.7336%)

since

2025/07/31

32.

Capital Group Investment Co of Amer Comp

(0.7097%)

since

2025/06/30

33.

American Funds Invmt Co of Amer A

(0.7097%)

since

2025/06/30

34.

iShares Russell Mid-Cap Growth ETF

(0.6217%)

since

2025/08/31

35.

The Health Care Select Sector SPDR® ETF

(0.6075%)

since

2025/08/31

36.

Vanguard Mid-Cap Value ETF

(0.5977%)

since

2025/07/31

37.

iShares MSCI USA Min Vol Factor ETF

(0.5951%)

since

2025/08/31

38.

JHancock Disciplined Value I

(0.5633%)

since

2025/07/31

39.

Vanguard Institutional Index I

(0.5379%)

since

2025/07/31

40.

JPM US Equity Income-Composite

(0.5158%)

since

2025/06/30

* Investors data is estimated based on stocks listed on Finnton that are currently held by Institution/Fund.

Earnings History

EPS ActualEPS EstimateEPS DifferenceSurprise Percent

Upcoming Earnings Release

Date

2025-12-31

EPS Estimate

3.97

Latest Release

Date

2025-09-30

EPS Actual

3.84

EPS Estimate

3.79

EPS Difference

0.05

Surprise Percent

1.3193%

Investing Fit Scorecard

(Last Updated 2025-09-30)

Deep Value
Potential Value Candidate(4)
Defensive
Moderately Defensive(4)
Dividend
Weak Dividend Profile(3)
Economic Moat
Some Competitive Advantage(5.8)
GARP
Not Attractive for GARP(2.5)
Growth
Weak Growth Prospect(3)
Momentum
Moderate Momentum(6)
Net Net
Not Undervalued (Net-Net)(2.5)
Quality
Low Quality Business(3)
Value
Overpriced(2.5)

Income Statement

(Last Updated 2025-09-30)

Revenue

$ 0

Cost Of Revenue

$ 0

Gross Profit

$ 0

Operating Expenses

$ 0

Operating Income

$ 0

Interest Expense

$ 0

Pretax Income

$ 0

Net Income

$ 0

Income Tax Expense

$ 0

EBITDA

$ 0

Total Other Income Expense Net

$ 0

Earnings Per Share

0

Dividends Per Share

0

Shares Outstanding

0

Operating Margin

0%

Trend

Balance Sheet

(Last Updated 2025-09-30)

Cash

$ 0

Short Term Investments

$ 0

Receivables

$ 0

Inventories

$ 0

Total Current Assets

$ 0

Property Plant Equipment

$ 0

Total Assets

$ 0

Payables

$ 0

Short Term Debt

$ 0

Long Term Debt

$ 0

Total Liabilities

$ 0

Equity

$ 0

Trend

Cash Flow

(Last Updated 2025-09-30)

Net Income

$ 0

Depreciation

$ 0

Change In Working Capital

$ 0

Cash From Operations

$ 0

Capital Expenditures

$ 0

Cash From Investing

$ 0

Cash From Financing

$ 0

Net Change In Cash

$ 0

Trend

Disclaimer: Finnton is a stock screener tool provided for informational and educational purposes only. The data, analysis, and insights offered on this website do not constitute financial, investment, tax, or legal advice. Users are solely responsible for their own investment decisions, and Finnton makes no guarantees regarding the accuracy, completeness, or reliability of the information provided. Past performance is not indicative of future results. Always conduct your own research and consult with a licensed financial advisor before making any investment decisions.